BACKGROUND The chemokine receptor CXCR5 is selectively expressed on B cells; it is involved in lymphocyte homing and the development of normal lymphoid tissue. Its principle ligand is CXCL13 or B lymphocyte chemoattractant. Three polymorphisms in the CXCR5 gene, rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A, have been identified. OBJECTIVE To assess the genetic polymorphisms of CXCR5 and evaluate their possible contribution to the susceptibility and response to therapy of diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS Fifty DLBCL (not otherwise specified) patients and 50 control subjects were included in this study. CXCR5 genotypes were determined by PCR-RFLP. RESULTS Our study revealed that the CXCR5 rs148351692 C/G and rs6421571 C/T gene polymorphisms are associated with an increased risk of developing DLBCL (OR 28.57 [95% CI 8.96-96.56] and 3.45 [1.67-11.83] respectively), while CXCR5 rs78440425 G/A showed no association with the risk of lymphoma. Moreover, the double and triple combined gene polymorphisms are associated with an increased risk of developing DLBCL of approximately 120-fold and 105-fold, respectively. CXCR5 gene polymorphisms had no significant impact on disease outcome or response to therapy. CONCLUSIONS CXCR5 gene polymorphisms could be considered a potential risk factor for the development of DLBCL.

中文翻译：

---

一组埃及弥漫性大 B 细胞淋巴瘤患者的 CXC 趋化因子受体 5 型基因多态性

背景趋化因子受体CXCR5在B细胞上选择性表达；它参与淋巴细胞归巢和正常淋巴组织的发育。其主要配体是 CXCL13 或 B 淋巴细胞趋化剂。CXCR5 基因中的三个多态性，rs148351692 C/G、rs6421571 C/T 和 rs78440425 G/A，已被确定。目的 评估 CXCR5 的遗传多态性，并评估它们对弥漫性大 B 细胞淋巴瘤 (DLBCL) 的易感性和治疗反应的可能贡献。患者和方法 本研究包括 50 名 DLBCL（未另外指定）患者和 50 名对照受试者。CXCR5 基因型由 PCR-RFLP 确定。结果 我们的研究表明，CXCR5 rs148351692 C/G 和 rs6421571 C/T 基因多态性与患 DLBCL 的风险增加有关（OR 28.57 [95% CI 8. 96-96.56] 和 3.45 [1.67-11.83]），而 CXCR5 rs78440425 G/A 显示与淋巴瘤风险无关。此外，双重和三重组合基因多态性与分别增加约 120 倍和 105 倍的 DLBCL 风险相关。CXCR5 基因多态性对疾病结果或治疗反应没有显着影响。结论 CXCR5 基因多态性可被认为是 DLBCL 发展的潜在危险因素。CXCR5 基因多态性对疾病结果或对治疗的反应没有显着影响。结论 CXCR5 基因多态性可被认为是 DLBCL 发展的潜在危险因素。CXCR5 基因多态性对疾病结果或治疗反应没有显着影响。结论 CXCR5 基因多态性可被认为是 DLBCL 发展的潜在危险因素。